Medicare Issues Final Local Coverage Decision For Bio-Techne’s ExoDx™ Prostate(IntelliScore) Test

Medicare Issues Final Local Coverage Decision For Bio-Techne's ExoDx™ Prostate(IntelliScore) Test Read MORE

MINNEAPOLIS, Oct. 10, 2019 /PRNewswire/ — Bio-Techne Corporation (NASDAQ:TECH) today announced that the Medicare Administrative Contractor (MAC) National Government Services, Inc. issued a final Local Coverage Decision (LCD) covering the ExoDx Prostate(IntelliScore) – EPI – test for men…

Share:

Author: HEDGE

Executive Editor and Founder of HEDGEaccordingly.com. Hedge Was Founded in January 22, 2008. Learn more about HEDGEaccordingly